

**David Callanan, M.D.**  
**Vitreoretinal Specialist**

**EDUCATION:**

1. Luther College

Decorah, Iowa  
B.A

1983      University of Iowa College of Medicine  
Iowa City, Iowa  
M.D.

**POST-GRADUATE TRAINING & EXPERIENCE:**

July 1983 to. Internship – Internal Medicine.  
June 1984      Parkland Memorial Hospital  
UT-Southwestern.  
Dallas, Texas.

July 1984 to. Residency – Internal Medicine.  
June 1985      Parkland Memorial Hospital  
UT-Southwestern.  
Dallas, Texas.

July 1985 to. Postdoctoral fellowship  
June 1987      Ocular Immunology - Supervisor: Jerry Y. Niederkorn,  
Ph.D.  
UT-Southwestern.  
Dallas, Texas.

July 1987 to. Residency –  
June, 1990      Ophthalmology  
Parkland Memorial Hospital  
UT-Southwestern.  
Dallas, Texas.

July 1990 to. Fellowship.  
June, 1991      Medical Retina - Supervisor: J. D. M. Gass, MD  
Bascom Palmer Eye Institute.  
Miami, Florida.

July 1991 to. Fellowship  
June 1992      Vitreoretinal Surgery - Supervisor: Victor Curtin, MD  
Bascom Palmer Eye Institute.

Miami, Florida

July 1992 to Fellowship  
Dec 1992 Uveitis – Supervisor: Robert Nussenblatt, MD  
National Eye Institute  
Bethesda, Maryland

Jan. 1993 Texas Retina Associates  
to present Dallas, Texas

### **CERTIFICATION**

November 24, 1991 -- American Board of Ophthalmology

### **LICENSE**

December 2, 1984 -- Texas State Board of Medical Examiners. #G7130

### **HONORS AND AWARDS**

Fort Worth Business Press: Healthcare Hero 2006

American Academy of Ophthalmology Achievement Award 2003

Best Doctors in America 2001, 2008

July 1985 to National Research Service Award

June 1987 National Eye Institute  
1F32EY05880-01

July 1990 to Heed Fellow

July 1991 Heed Ophthalmic Foundation

### **APPOINTMENTS**

Clinical Associate Professor  
University of Texas Southwestern Medical School  
Dallas Texas

## **MEMBERSHIPS**

American Academy of Ophthalmology  
The Association for Research in Vision and Ophthalmology  
The American Uveitis Society  
American Society of Retina Specialists  
International Ocular Inflammation Society  
Pan-American Association of Ophthalmology  
Texas Medical Association  
Texas Ophthalmological Association  
Tarrant County Medical Society  
Dallas Academy of Ophthalmology  
Tarrant County Ophthalmology Society

## **RESEARCH AND CLINICAL STUDIES**

Principal Investigator:

A Multicenter, Randomized, Single-Masked Study Comparing  
Reduced-fluence Visudyne-Lucentis Combination Therapies and  
Lucentis Monotherapy in Subjects with CNV Secondary to AMD.  
QLT, Inc.  
Ongoing

Principal Investigator

The Natural history of Geographic Atrophy Progression (GAP) Seconda  
Age-Related Macula Degeneration (AMD).  
Alcon  
Ongoing

Principal Investigator:

A 12-Month, Open-Label Trial to Assess the Safety of 50 ug  
Brimonidine Tartrate Posterior Segment Drug Delivery System  
(Brimonidine Tartrate PS DDS) Applicator System in Patients with  
Diabetic Macular Ischemia.  
Allergan  
Ongoing

Principal Investigator

A Phase II Multicenter, Randomized, Double-Masked, Placebo-Control  
Dose-Comparison Study of the Safety and Efficacy of Fenretinide in th  
Treatment of Geographic Atrophy in Subjects with Age-Related Macul  
Degeneration.  
Sirion  
Recruitment completed

Principal Investigator:

Lucentis and Reduced Fluence PDT for Choroidal Neovascularization in Age-Related Macular Degeneration (RAP trial).

Novartis

Ongoing

Principal Investigator:

Compassionate Use of Anecortave Acetate 3% for Reduction of Steroid-Induced Elevated Intraocular Pressure.

Alcon

Ongoing

Principal Investigator:

A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up To 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects With Diffuse Diabetic Macular Edema (DME).

Allergan

Ongoing

Principal Investigator:

An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate or Posterior Uveitis.

Allergan

Ongoing

Principal Investigator:

Diabetic Retinopathy Clinical Research Network: A Phase II Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema:

Bevacizumab.

National Institutes of Health

Ongoing

Principal Investigator:

Diabetic Retinopathy Clinical Research Network: A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema.

National Institutes of Health

Ongoing

Principal Investigator:

A Double-Masked, Placebo-Controlled, Multi-Center, Dose Ranging

Study to Assess the Efficacy and Safety of LX211 as Therapy in  
Subjects with Active Sight Threatening, Non-Infectious Uveitis.  
Lux BioSciences  
Ongoing

Principal Investigator:

Protocol J: Diabetic Retinopathy Clinical Research Network  
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive  
Treatment to Panretinal Photocoagulation for Proliferative Diabetic  
Retinopathy.  
National Institutes of Health  
Ongoing

Principal Investigator:

Diabetic Retinopathy Clinical Research Network: A Pilot Study of  
Laser Photocoagulation for Diabetic Macular Edema.  
National Institutes of Health  
Ongoing

Principal Investigator:

Standard Care vs. Corticosteroid for Retinal Vein Occlusion Study.  
National Institutes of Health  
Enrollment completed

Principal Investigator:

Next Generation Ophthalmic Irrigating Solution Posterior Segment  
Safety Study.  
Alcon  
Enrollment finished

Principal Investigator:

A Multicenter, Randomized, Double-masked, Controlled Study to  
Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone  
Acetonide Implant in Patients with Non-infectious Uveitis Affecting  
the Posterior Segment of the Eye.  
Bausch & Lomb 415-001  
Closed

Principal Investigator:

A Multicenter, Randomized, Masked, Controlled Study to Evaluate  
the Safety and Efficacy of a 0.6 mg Intravitreal Fluocinolone Implant  
in Patients with Diabetic Macular Edema.  
Control Delivery Systems FL-002  
Closed

Principal Investigator:

A Multicenter, Randomized, Masked, Controlled Study to Evaluate  
Retisert, an Intravitreal Fluocinolone Acetonide Implant, in the  
Treatment of Patients with Diabetic Macular Edema.  
Control Delivery Systems FL-005

Closed

Principal Investigator:

A Multi-center, Randomized, Prospective Phase I/II Clinical Trial to Study the Effects of Cyclooxygenase-2 Inhibition on the Response to Photodynamic Therapy in Patients with Age-Related Macular Degeneration.

Pharmacia

Closed

Principal Investigator:

Submacular Surgery Trials.

NIH

Closed

Investigator:

Protein Kinase CB Inhibitor – Diabetic Macular Edema Study.

Lilly Research Laboratories

Ongoing

Investigator:

A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-dose Intravitreal Injections of rhuFab V2 in combination with Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Neovascular Age-related Macular Degeneration.

Genentech

Closed

Investigator:

Verteporfin in Photodynamic Therapy Trial.

QLT and Ciba Vision

Closed

Investigator:

Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study. QLT and CibaVision.

Closed

Investigator:

Visudyne in Macular Degeneration

QLT and CibaVision

Closed

Investigator:

Choroidal Neovascularization Prevention Trial

Funded by NIH

Closed

Investigator:

A Randomized, Controlled Study of the Safety and Preventative Efficacy of Oral Ganciclovir When Used in conjunction with an Intravitreal Ganciclovir Implant in the Treatment of Cytomeglovirus Retinitis.

Sponsored by Syntex Corporation

Closed

Investigator:

Multicenter Open Label Protocol to Evaluate the Use of an Intravitreal Ganciclovir Implant in Patients with Sight-Threatening Cytomeglovirus Retinitis and No Central Venous Access.

Sponsored by Chiron

Closed

Investigator:

Clinical Investigation of Perfluoron for Ophthalmic Surgery

Infinitech Corporation

Closed

Investigator:

Dose-Ranging Safety and Efficacy Study Comparing Interferon ALFA-2a Treatment

Funded by Hoffmann-La Roche, Inc.

Closed

Investigator:

Evaluation of OC-2 In the Inhibition of Cataract Formation

Associated with Vitrectomy Surgery

Sponsored by Oculon corporation

Closed

Investigator:

Richard James' Silicone Oil Study

Sponsored by the Richard James Company

Closed

## PUBLICATIONS

**Callanan DG**, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of Posterior Uveitis with a Fluocinolone Acetonide Implant: 3-Year Clinical Trial Results. Submitted for publication.

Williams P, Chan CC, Buggage R, Srivastava S, **Callanan D**. Pituitary Adenoma Presenting as Bilateral Bullous Exudative Retinal Detachments: A Clinicopathologic Report. Submitted for publication.

Witherspoon SR, **Callanan D**. Celiac Disease Presenting as a

Xerophthalmic Fundus. Accepted. Retina.

**Callanan DG.** Novel Intravitreal Fluocinolone Acetonide Implant in the Treatment of Chronic Noninfectious Posterior Uveitis. *Expert Rev. Ophthalmol* 2007;2:33-44.

Goldstein DA, Godfrey DG, Hall A, **Callanan DG**, Jaffe GJ, Pearson PA, Usner DW, Comstock TL. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. *Arch Ophthalmol* 2007;125:1478-1485.

Hariprasad SM, **Callanan D**, Gainey S, He YG, Warren K. Cystoid and diabetic macular edema treated with nepafenac 0.1%. *J Ocul Pharmacol Ther* 2007;23:585-590.

Fong DS, Strauber SF, Aiello LP, Beck RW, **Callanan DG**, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Lauer AK, Recchia FM, Solomon SD. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007;125:469-480.

Nguyen QD, **Callanan D**, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage: proceedings of an expert panel roundtable discussion. *Retina* 2006;Suppl:1-16.

**Callanan D**, Scott IU, Murray TG, Oxford KW, Bowman CB, Flynn, Jr., HW. Early Onset Endophthalmitis Caused by *Aspergillus* Species Following Cataract Surgery. *Am J Ophthalmol.* 2006;142:509-511.

Jaffe GJ, Martin DF, **Callanan D**, Pearson PA, Levy B, and Fluocinolone Acetonide Uveitis Study Group. Fluocinolone Acetonide Implant (Retisert™) for Non-infectious, Posterior Uveitis: 34-week Results of a Multicenter Randomized Clinical Study. *Ophthalmology.* 2006;113:1020-1027.

Quillen DA, Davis JB, Gottlieb JL, Blodi BA, **Callanan DG**, Chang TS, Equi RA. The White Dot Syndromes. *Am J Ophthalmol.* 2004; 137:538-550.

Busquets MA, Shah G, Wickens J, **Callanan D**, Blinder KJ, Burgess D, Grand MG, Holekamp NM, Boniuk I, Joseph DP, Thomas MA, Fish GE, Bakal J, Hollands H, Sharma S. Ocular Photodynamic Therapy with Verteporfin for Choroidal Neovascularization Secondary to Ocular Histoplasmosis Syndrome. *Retina.* 2003;23:299-306.

Buggage RR, **Callanan DG**, Shen DF, Chan CC. Propionibacterium acnes endophthalmitis diagnosed by microdissection and PCR. *Br J Ophthalmol.* 2003; 87:1190-1.

Solley WA, Martin DF, Newman NJ, King R, **Callanan DG**, Zacchei T,

Wallace T, Parks DJ, Bridges W, Sternberg, P Jr. Cat scratch disease: posterior segment manifestations. *Ophthalmol.* 1999;106:1546-53.

**Callanan DG**, Fellman RL, Savage JA. Latanoprost-associated Cystoid Macular Edema. *Am J Ophthalmol* 1998; 126:134-5

**Callanan DG**, Fish GE, Anand R. Reactivation of Inflammatory Lesions in Ocular Histoplasmosis. *Arch Ophthalmol* 1998;116:470—474

**Callanan DG**, Blodi BA, Martin DF. Macular Edema Associated with Nicotinic Acid (Niacin) *JAMA* 1998;279:1702

**Callanan DG**, Jost BF. New Findings in Ocular Histoplasmosis. *Curr Opin Ophthalmol.* 1995;6:8-12

Cheung MK, Martin DF, Chan CC, **Callanan DG**, Cowan CL, Nussenblatt RB. Diagnosis of Reactive Lymphoid Hyperplasia by Choroidretinal Biopsy. *Am J Ophthalmol* 1994;118:457-62

Van Newkirk MR, Gass JF, **Callanan DG**, Byrne SF, Hughes JR. Follow-up and Ultrasonographic Examination for Patients with Macular Pseudo-operculum. *Am J Ophthalmol* 1994; 117: 12-18

**Callanan DG**, Lewis ML, Byrne SF Gass DM. Choroidal Neovascularization Associated with Choroidal Nevi. *Arch Ophthalmol.* 1993;111:789-94

**Callanan DG**, Borup MD, Newton J, Smiddy WE. Accidental Skin Punctures During Ophthalmic Surgery. *Ophthalmology.* 1993;100:1846-1850.

**Callanan DG**, Rubsamén PE. Moraxella Infection of a Scleral Buckle. *Am J Ophthalmol.* 1992;114:637-8

Gass JDM, **Callanan DG**, Bowman CB. Oral Therapy in Diffuse Unilateral Subacute Neuroretinitis. *Arch Ophthalmol.* 1992;110:675-80.

Gass JD, **Callanan DG**, Bowman CB. Successful Oral Therapy for Diffuse Unilateral Subacute Neuroretinitis. *Trans Am Ophthalmol Soc* 1991; 89:97-112

He YG, Ross J, **Callanan DG**, Niederkorn JY. Acceptance of H-Y Disparate Corneal Grafts Despite Concomitant Immunization of the Recipient. *Transplantation.* 1991;51:532-536

Ross J, **Callanan D**, Kunz H, Niederkorn JY. Evidence that the fate of class II-disparate corneal grafts is determined by the timing of class II expression. *Transplantation.* 1991; 51: 532-536.

Niederkorn JY, **Callanan DG**, Ross JR. Prevention of the Induction of Allo-specific Cytotoxic T Lymphocyte and Delayed-type Hypersensitivity

Responses by Ultraviolet Irradiation of Corneal Allografts. *Transplantation*. 1990;50:281-286

**Callanan DG**, Luckenbach M, Fischer B, Peeler JS, Niederkorn JY. Histopathology of Rejected Orthotopic Corneal Allografts in the Rat. *Invest Ophthalmol Vis Sci*. 1989;30:413-424.

Niederkorn JY, Peeler JS, Ross J, **Callanan DG**. The Immunogenic Privilege of Corneal Allografts. *Regional Immunology* 1989;2:117-124.

Peeler JS, **Callanan DG**, Luckenbach MW and Niederkorn JY. Presentation of the OH-Y Antigen on Langerhans Cell-Negative Corneal Grafts Downregulates the Cytotoxic T Cell Response and Converts Responder Strain Mice into Phenotypic Non-responders. *J of Exp. Med.* 1988; 168: 1749-1766

**Callanan DG**, Peeler J, and Niederkorn JY. Characteristics of Rejection of Orthotopic Corneal Allografts in the Rat. *Transplantation* 1988; 45: 437-443.

Hubel KA and **Callanan DG**. Effects of Calcium on Iliac Transport and Electrically Induced Secretion. *American Journal of Physiology* 1980; 239(1): G 18-22

### **BOOK CHAPTERS**

**Callanan D**. Intraocular Corticosteroid Implants. Surgical Management of Inflammatory Eye Disease. Eds. Becker and David. Springer-Verlag. 2008.

Williams P. and **Callanan D**. Retinal Toxicity of Systemic Medication. *Albert and Jakobiec's Principles and Practice of Ophthalmology*. 3<sup>rd</sup> Edition. In press.

**Callanan DG**. Drug toxicities. *Clinical Retina*. Eds. Quillen and Blodi. AMA Press: Chicago, 2002.

**Callanan D**. Case Series Epidemiology. Basic and Clinical Science Course. American Academy of Ophthalmology: San Francisco, 2002.

**Callanan D**. Chapter 19: Toxic retinopathies. *Text Atlas of the Retina*. Eds. Hamilton, Gregson, and Fish. Martin Dunitz Ltd.: London, 1998.

## CLINICAL TRIAL PUBLICATIONS

Guidelines for Interpreting Retinal Photographs and Coding Findings in the Submacular Surgery trials: SSt report NO. 8. Submacular Surgery Trials Research Group.

Histo-pathological and Ultrastructural Features of Surgically-excised Subfoveal Choroidal Neovascular Lesions: SST Report NO. 7. Submacular Surgery Trials Research Group.

Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin: Two-year Results of 2 Randomized Clinical Trials –TAP report No. 2. *Arch Ophthalmol.* 2001;119:198-207.

Verteporfin in Photodynamic Therapy Study Group. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions with Occult but no Classic Neovascularization – Verteporfin in Photodynamic Therapy Report No. 2. *Am J Ophthalmol.* 2001;131:541-560.

Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia with Verteporfin: One-year Results of a Randomized Clinical Trial – VIP Report No. 1. *Ophthalmol.* 2001;108:841-852.

Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin. *Arch Ophthalmol.* 1999;117:1329-45.

The Choroidal Neovascularization Prevention Trial Research Group. Choroidal Neovascularization in the Choroidal Neovascularization Prevention Trial. *Ophthalmol* 1998;105:1367-72

The Choroidal Neovascularization Prevention Trial Research Group. Laser Treatment in Eyes with Large Drusen: Short Term Effects Seen in a Pilot Randomized Clinical Trial. *Ophthalmology.* 1998;105:11-23

Pharmacological Therapy for Macular Degeneration Study Group. Interferon Alfa-2a is Ineffective for Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration. Results of a Prospective Randomized Placebo-controlled clinical Trial. *Arch. Ophthalmol.* 1997;115-865-72

## **POSITIONS HELD**

President, Ophthalmic Partners, P.A. 1998 to 2004.

Chairman, Credentials Committee, Arlington Memorial Hospital, Arlington, Texas. 2000 to 2003.

Chairman, Department of Ophthalmology & Otolaryngology, Arlington Memorial Hospital, Arlington, Texas. 1998-2000.

Alcon Retinal Advisory Council II. 2000 to present.

Bausch & Lomb Uveitis Advisory Group. 2004 to present.

Orbis volunteer

## **INVITED PRESENTATIONS**

American Academy of Ophthalmology Retina Subspecialty Day. "Combination Therapy for Macular Degeneration: Ranibizumab and Reduced Fluence PDT". November 9, 2007. New Orleans, LA.

Allergan Retinal Fellows Meeting. "New Therapies in Macular Degeneration: Anti-VEGF and Beyond". September 28, 2007. Newport Beach, CA.

International Ocular Inflammation Society. "Management of Inflamed Eyes Undergoing Surgery". September 18, 2007. Paris, France.

Angiogenesis 2007. "Combination Anti-VEGF and Photodynamic Therapy for AMD". February 24, 2007. Miami, FL.

Twenty-first Sarasota Vitreo-retinal Update Course . "Uveitis for Dummies", "AMD Combination Therapy: What, When, and Why", "A Novel Use for Anecortave Acetate". February 9-10, 2007. Sarasota, FL.

Second International Symposium. Argentina Society of Retina and Vitreous. "Combination Therapy for Age Related Macular Degeneration", "Update on the Diabetic Retinopathy Clinical Research Network", "Retinal Vasculitis". October 14, 2006. Buenos Aires, Argentina.

AMD Roundtable. Combination Therapy: From Theory to Practice. "Avastin and Reduced Fluence PDT for Choroidal Neovascularization". September 10, 2006. Cannes, France.

Research Advances in Ocular Oncology: Focus on Translational Applications. "Staging of Ocular Disease: Importance of Imaging and Pathologic Confirmation". April 29, 2006. ARVO. Fort Lauderdale, FL.

Symposium at ZhongShang Ophthalmic Center of Sun Yat-Sen University.

April 19, 2006. Guangzhou, China

Retinal Symposium. Eye Hospital of Wenzhou Medical College. April 17, 2006. Wenzhou, China.

Shanghai International Ophthalmic Symposium. "Macular Degeneration Update", "Steroids and Uveitis", "Uveitis Masquerade Syndromes". April 15, 2006. Shanghai, China.

Colorado Society of Eye Physicians and Surgeons. 91<sup>st</sup> Annual Meeting. "White Dot Syndromes", "Steroids and Uveitis", Current Treatments for Macular Degeneration", "Masquerade Syndromes". January 27-29, 2006. Beaver Creek, Colorado.

Austin Ophthalmological Society. "Macular Degeneration 2005". August 11, 2005. Austin, TX.

Arizona Ophthalmological Society Tri-State Meeting. "Lymphoma and the Eye", "Steroids and Uveitis". May 21-22, 2005. Phoenix, AZ.

Ophthalmology Update for the Primary Care Physician. "Uveitis and Systemic Diseases", "Diabetes and its Impact on Eyes". May 6, 2005. Univ. of Nebraska Medical Center. Omaha, NE.

33<sup>rd</sup> Aspen Retinal Detachment Society Meeting. "Combination therapies for Macular Degeneration", "Update on Intraocular Lymphoma". March 6-10, 2005. Aspen, CO

Uveitis for the Other Specialist. "Masquerade Syndromes", "Drug Delivery Devices: Implantation", "Integrating Uveitis into a Retinal Practice". February 4-5, 2005. Miami, FL.

Tri-State Ophthalmological Conference. "Steroids and the Retina", "25 Gauge Vitrectomy". September 24, 2004. Branson, Missouri.

American Uveitis Society. Fluocinolone Acetonide Intravitreal Implant for the Treatment of Uveitis Affecting the Posterior Segment: 34 Week Results of a Randomized, Masked, Multi-center Clinical Trial  
. Fluocinolone Acetonide Uveitis Study Group. January 19, 2004. Vail, CO.

Presbyterian Eye Meeting. "Uveitis for Dummies". April 25, 2003. Dallas, TX.

International Society of Ocular Toxicology. "The Use of a Fluocinolone Acetonide Implant for Uveitis and Diabetic Macular Edema". September 9, 2002. Lindau, Germany.

National Eye Institute Alumni Meeting. "The Use of Fluocinolone in Uveitis". September 20, 2002. Bethesda, MD.

Texas Medical Association Annual Meeting. "A New Therapy for Uveitis". April 19, 2002. Dallas, TX.

American Academy of Ophthalmology Annual Meeting Course. "Current Topics in Posterior Uveitis". 2000, 2001.

American Academy of Ophthalmology Annual Meeting Course. "Surgical Management of Diabetic Tractional Retinal Detachment". 1998 through 2001.

Am. Society of Ophthalmic Registered Nurses Regional Education Mtg. "Macular Degeneration Update". August 23, 1997. Ft. Worth, Texas.

Asociacion de Retina de Occidente, A.C.. Course Coordinator: The Meeting on Silicone Oil. June 6-7, 1997. Guadalajara, Mexico.

Asociacion de Retina de Occidente, A.C.. Course Director. The New Age of Perfluorocarbon Liquids. November 22-23, 1996. Leon, Mexico.

Southern Retina Study Club. San Antonio. 1996

Am. Uveitis Society. "Masquerade syndromes revisited". Oct. 28, 1996. Chicago, IL.

Am. Uveitis Society. "Reactivation of inflammatory lesions in ocular histoplasmosis syndrome". October 30, 1995. Atlanta, GA.

Montreal International Uveitis Meeting. Montreal, Canada. 1995

Am. Society of Ophthalmic Registered Nurses. "Posterior uveitis". November 1, 1995. Atlanta, GA.

Am. Society of Ophthalmic Registered Nurses. "Macular Hole", "Macular degeneration". June 12, 1993. Dallas, TX .

Assoc. for Research in Vision and Ophthalmology. "Cone perimetry in macular holes: pre- and post-vitreotomy". May, 1993. Sarasota, FL.

Florida Society of Ophthalmology. "Diffuse unilateral subacute neuroretinitis". June 6, 1992. Palm Beach Gardens, FL.

Am. Society of Ophthalmic Registered Nurses. "Macular Degeneration". February 8, 1992. Miami, FL.

CURSO. "Drug toxicity", "Retinal detachment", "Inflammatory conditions of the retina". May 23-24, 1991. Puerto Rico, FL.

